| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 19.9MM | +0% |
| Gross Profit | 17.7MM | - |
| Cost Of Revenue | 2.1MM | -4% |
| Operating Income | -2.5MM | +48% |
| Operating Expenses | 20.2MM | - |
| Net Income | -10MM | +7% |
| R&D | 1.3MM | +0% |
| G&A | 19MM | +5% |
| Interest Expense | 5.1MM | +3% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
OptiNose, Inc. ( NASDAQ:OPTN ) shareholders should be happy to see the share price up 13% in the last quarter. But will...
YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 10, 2024 at 2:15 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will
ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical trial program also showed reduction in sinus inflammation and in acute exacerbations, which frequently result in use of antibiotics XHANCE uses the proprietary Exhalation Delivery System to enable deposition of a proven steroid in target areas of inflammation deep in the nose not typically reached by s
It's been a mediocre week for OptiNose, Inc. ( NASDAQ:OPTN ) shareholders, with the stock dropping 12% to US$1.68 in...
OptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Call Transcript March 7, 2024 OptiNose, Inc. beats earnings expectations. Reported EPS is $-9.0E-5, expectations were $-0.1. OPTN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you for standing by. […]
OptiNose ( NASDAQ:OPTN ) Full Year 2023 Results Key Financial Results Revenue: US$71.0m (down 6.9% from FY 2022). Net...
Q4 2023 OptiNose Inc Earnings Call
Comprehensive Financial Summary and Outlook for 2024
OptiNose (OPTN) delivered earnings and revenue surprises of 10% and 0.18%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis Physicians diagnose chronic sinusitis 10 times more frequently than XHANCE’s current nasal polyps indication and there is no FDA-approved medication for these patients Company reports fourth quarter and full year 2023 XHANCE net revenue of $19.9 million and $71.0 million Conference call and webcast to be held toda